CAR T-cell therapy

  • February 8, 2022  

    Facing Esophageal Cancer in 2022

    Kaumudi Bhawe, PhD

    Difficulty swallowing, a hoarse voice, or heartburn has led to the dreaded diagnosis of esophageal cancer. What now? Origin, Types, and Stages of Esophageal Cancer If you or a loved one face esophageal cancer, it can be helpful to start by learning more about the disease and your particular diagnosis. Then, you will be prepared to learn about esophageal cancer treatments. Esophageal cancer originates… Read more »

  • January 31, 2022  

    NCCN Guidelines for Patients: Cervical Cancer Bookmark

    George Lundberg, MD

    The nonprofit National Comprehensive Cancer Network (NCCN) publishes guidelines for patients to learn more about their diagnosis and their treatment options. Here is their 2022 update for cervical cancer.

    .

  • October 18, 2021  

    Novel Car-T Shows ‘Promising Early Signs of Clinical Efficacy’ for Diffuse Midline Gliomas Bookmark

    George Lundberg, MD

    Healio outlines results from a Stanford University study suggesting that a type of treatment known as CAR T-cell therapy is promising for children with diffuse midline gliomas. The treatment is still in an early phase of testing in humans.

    .

  • August 26, 2019  

    CAR T-cell Therapy for HPV-Induced Metastatic Cervical Cancer Bookmark

    George Lundberg, MD

    Research paper from the Journal of Clinical Oncology, selected by Editor in Chief George Lundberg, MD, who notes:

    CAR T-cell therapy has been approved by the U.S. Food and Drug Administration (FDA) for certain hematologic malignancies. This early study demonstrates its effectiveness in human papillomavirus (HPV)-induced metastatic cervical cancer as well.

    Go to full article published by the Journal of Clinical Oncology.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • June 24, 2019  

    Regional Delivery of Mesothelin-Targeted CAR T-Cell Therapy Creates a Win for Solid Tumors Bookmark

    Emma Shtivelman, PhD

    Excerpt:

    “In patients with malignant pleural disease, autologous mesothelin-targeted chimeric antigen receptor (CAR) T-cell therapy demonstrated clinical benefit with no significant toxicity, outcomes that may be due to the regional delivery of the CAR T cells to the intrapleural cavity rather than conventional systemic delivery. The phase I trial (ClinicalTrials.gov identifier: NCT02414269) results were presented at the 2019 American Association for Cancer Research (AACR) Annual Meeting, held March 29–April 3 in Atlanta, Georgia (abstract CT036).”

    Go to full article published by Cancer Network on April 10, 2019.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

     

  • September 6, 2017  

    A Cancer Doctor Weighs In On CAR-T, Precision Medicine And Pricing Debates Bookmark

    Emma Shtivelman, PhD

    Excerpt:

    “Yesterday’s historic FDA approval of the first engineered T-cell treatment for cancer, Novartis’ Kymriah (tisagenlecleucel), was accompanied by inevitable questions about how the product would be priced. In the end, Novartis set the price at $475,000, which was lower than many analysts had predicted, considering the treatment is designed to cure some forms of acute lymphoblastic leukemia (ALL)—and in clinical trials it did just that for most patients.”

    Go to full article published by Forbes on Aug 31, 2017.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • August 10, 2017  

    Reengineering Immune System Cells to Treat Glioblastoma

    Emma Shtivelman, PhD

    Glioblastoma multiforme (GBM) is a serious diagnosis. The search for better treatments is ongoing, but with little to show since the U.S. Food and Drug Administration (FDA) approved the use of the chemotherapy drug temozolomide with concurrent radiation 12 years ago, based on data showing modest improvement in patients’ survival. By now, a new cancer treatment approach known as CAR T-cell therapy is famous… Read more »